Your browser is no longer supported. Please, upgrade your browser.
APLS Apellis Pharmaceuticals, Inc. daily Stock Chart
APLS [NASD]
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.74 Insider Own20.70% Shs Outstand73.98M Perf Week-6.06%
Market Cap2.88B Forward P/E- EPS next Y-4.80 Insider Trans0.00% Shs Float56.05M Perf Month-9.53%
Income-227.90M PEG- EPS next Q-1.14 Inst Own62.30% Short Float11.90% Perf Quarter39.97%
Sales- P/S- EPS this Y-126.40% Inst Trans8.46% Short Ratio4.54 Perf Half Y32.63%
Book/sh2.19 P/B17.78 EPS next Y-13.50% ROA-69.90% Target Price50.20 Perf Year180.75%
Cash/sh5.87 P/C6.64 EPS next 5Y- ROE-133.20% 52W Range13.04 - 45.04 Perf YTD27.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.63% Beta-
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low184.51% ATR1.95
Employees87 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)39.60 Volatility3.99% 4.58%
OptionableYes Debt/Eq1.01 EPS Q/Q-73.20% Profit Margin- Rel Volume0.60 Prev Close38.94
ShortableYes LT Debt/Eq1.01 EarningsFeb 25 Payout- Avg Volume1.47M Price37.10
Recom2.10 SMA20-11.58% SMA501.42% SMA20030.06% Volume637,787 Change-4.73%
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Aug-01-19Reiterated Cantor Fitzgerald Overweight $52 → $50
Jul-12-19Upgrade JP Morgan Neutral → Overweight $35 → $49
Mar-29-19Initiated Robert W. Baird Outperform $45
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Jul-30-18Upgrade B. Riley FBR Neutral → Buy $27
May-24-18Initiated Cantor Fitzgerald Overweight $52
Apr-12-18Downgrade B. Riley FBR, Inc. Buy → Neutral $27
Feb-08-18Initiated B. Riley FBR, Inc. Buy $27
Feb-06-20 01:23PM  CEO council reveals innovation center location, plans international summit American City Business Journals
Jan-16-20 04:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-15-20 05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-13-20 04:57PM  Apellis Pharmaceuticals' stock offering closes $50M higher than expected American City Business Journals
12:10PM  Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
09:39AM  Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019 Insider Monkey
Jan-09-20 02:18PM  Apellis Pharmaceuticals is planning to raise $350M here's how American City Business Journals -5.21%
Jan-08-20 09:30PM  Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
10:07AM  Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data Zacks
08:12AM  The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results Benzinga
07:48AM  Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study Zacks
Jan-07-20 04:15PM  This Biotech Just Topped Alexion's Biggest Moneymaker And Rocketed Investor's Business Daily +28.29%
04:11PM  Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
01:34PM  Publicly traded company moves HQ out of Louisville area American City Business Journals
12:02PM  Can a Drug's $500,000 Price Withstand Competition? Bloomberg
10:29AM  Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion Barrons.com
10:26AM  Waltham biotech's drug bests Alexion's blockbuster Soliris in new trial American City Business Journals
09:24AM  Apellis stock soars on positive data for potential Soliris competitor MarketWatch
07:00AM  Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) GlobeNewswire
06:38AM  Apellis Pharmaceuticals Soars as Blood-Drug Test Outperforms Alexion's Therapy TheStreet.com
Jan-02-20 07:00AM  Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-09-19 08:48AM  Are Options Traders Betting on a Big Move in Apellis Pharmaceuticals (APLS) Stock? Zacks
Dec-06-19 04:11PM  Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS) Insider Monkey -7.20%
Nov-26-19 07:00AM  Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-15-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-08-19 10:00AM  Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week GlobeNewswire
Nov-07-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-05-19 07:30AM  Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results GlobeNewswire
Oct-28-19 09:26AM  Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds? Insider Monkey
Oct-16-19 11:43AM  Alexion makes $930M acquisition in bid to bolster blockbuster drug American City Business Journals +6.34%
Oct-11-19 04:01PM  Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019 GlobeNewswire
Oct-04-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-03-19 08:37AM  Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2% Zacks
Sep-27-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-19 08:00AM  Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-18-19 08:00AM  Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration GlobeNewswire
Sep-16-19 05:00PM  Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes GlobeNewswire
Sep-13-19 07:31AM  Powerful CEO council to establish investment fund American City Business Journals
Sep-12-19 08:22AM  Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes GlobeNewswire -10.67%
Sep-11-19 04:38PM  Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes GlobeNewswire
Sep-09-19 05:00PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-03-19 08:00AM  Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire -5.81%
Aug-28-19 05:00PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-19 11:31AM  Should Amgen Finally Buy Alexion Pharmaceuticals? Motley Fool
Aug-16-19 05:00PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-02-19 06:00AM  CEO Survey: Cedric Francois, Apellis Pharmaceuticals American City Business Journals
Jul-31-19 05:00PM  Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results GlobeNewswire
Jul-26-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-22-19 02:34PM  Apellis expands C-suite amid plans to double its workforce American City Business Journals +7.25%
07:35AM  Apellis Pharmaceuticals expanding product pipeline American City Business Journals
07:00AM  Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer GlobeNewswire
Jul-18-19 07:00AM  Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies GlobeNewswire
Jul-14-19 07:03PM  3 Biotech Stocks That Could Double Your Money Motley Fool
Jul-12-19 09:42AM  Apellis Pharma Climbs on Upgrade to Overweight at JP Morgan TheStreet.com
Jul-08-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-27-19 07:39AM  Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab GlobeNewswire
Jun-19-19 09:31PM  Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS) Insider Monkey
Jun-15-19 10:00AM  Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress GlobeNewswire
Jun-06-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-31-19 07:13AM  Investors Who Bought Apellis Pharmaceuticals (NASDAQ:APLS) Shares A Year Ago Are Now Up 10% Simply Wall St. -7.12%
May-24-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-13-19 05:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-09-19 11:24AM  Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS) Insider Monkey
May-08-19 07:00AM  Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results GlobeNewswire
Apr-30-19 01:49PM  Apellis executives got a raise 2018 and will get another in 2019 American City Business Journals
Apr-05-19 04:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-22-19 04:30PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-12-19 06:00PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-11-19 04:01PM  Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire
Mar-07-19 07:00AM  Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Mar-06-19 04:00PM  Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-05-19 11:15AM  Apellis resumes trial after safety investigation American City Business Journals
Mar-04-19 04:00PM  Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire
07:00AM  Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy GlobeNewswire
Feb-28-19 02:26PM  Apellis lands as much as $250M in financing from drug development company American City Business Journals +6.39%
10:00AM  Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications GlobeNewswire
Feb-26-19 05:00PM  Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-12-19 06:00PM  Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-11-19 07:00AM  Apellis Pharmaceuticals APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Feb-05-19 12:02PM  Apellis APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia GlobeNewswire
Jan-31-19 09:00AM  Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe GlobeNewswire
Jan-14-19 08:42AM  Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher Zacks
Jan-02-19 07:00AM  Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 12:51AM  Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy? Insider Monkey
Dec-20-18 04:01PM  Apellis Pharmaceuticals APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy GlobeNewswire
07:00AM  Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy GlobeNewswire
Dec-16-18 02:18PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-08-18 10:02AM  The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings Benzinga
Dec-03-18 01:01PM  Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH GlobeNewswire +17.73%
Dec-02-18 12:01PM  Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH GlobeNewswire
Nov-20-18 07:00AM  Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer GlobeNewswire
Nov-19-18 08:30AM  Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-13-18 10:41AM  Enable Injections inks development deals with pharma firms American City Business Journals
08:00AM  Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results GlobeNewswire
Nov-07-18 04:30PM  Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire +5.35%
Nov-01-18 10:50AM  Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting GlobeNewswire +7.15%
Oct-18-18 02:56PM  Apellis shares plunge after incident in two clinical trials American City Business Journals -17.06%
Oct-01-18 01:49PM  EXCLUSIVE: Apellis CEO says company has no plans to move its HQ American City Business Journals
Sep-28-18 09:00AM  Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.